AC Immune partner LMI images 1st patient in ADvance trial of PI-2620 for AD

AC Immune announced that its collaboration partner, Life Molecular Imaging or LMI , has imaged the first patient in ADvance, the pivotal Phase 3 trial of PI-2620, a Tau PET imaging agent for AD orAlzheimer’s disease. PI-2620 was discovered in collaboration between AC Immune and LMI and is developed under a strategic collaboration and exclusive licensing agreement with LMI.Dr. Andrea Pfeifer, Chief Executive Officer of AC Immune SA, commented: "We are delighted to see LMI launching this pivotal Phase 3 trial of PI-2620, our next generation, potentially best-in-class Tau PET tracer. The ability to detect and quantify aggregated Tau with enhanced sensitivity and specificity, will improve our diagnostic confidence and accelerate clinical development of therapeutic interventions. This development underscores the strength of our Morphomer platform which continues to generate excellent candidates against multiple pathological proteins involved in neurodegenerative diseases. "This histopathology study’s objective is to confirm the tracer’s safety, diagnostic efficacy and accuracy in detecting and staging Tau pathology of PI-2620 before seeking market approval. The decision to advance PI-2620 into Phase 3 development in AD was supported by Phase 2 results presented at this year’s Alzheimer’s Association International Conference .